GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,422,547, covering protein expression methods for the production of polyclonal antibodies from natural immune repertoires. GigaGen has exclusive rights to the patented technology and is […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-09-13 13:58:592020-06-02 09:41:26GigaGen Announces Issue of US Patent for Polyclonal Antibody Production
GigaGen’s development of the world’s first synthetic immune system was covered recently in the Biospace.com story Bay Area’s GigaGen Develops Synthetic Immune System to Harness Antibodies. According to the article, “The development of therapeutics that harness the body’s immune system has exploded in popularity among biotech companies with many investing heavily in research and […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-04-19 20:11:442017-12-19 13:02:45GigaGen Highlighted in Biospace.com Story
GigaGen Inc., a world leader in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has achieved all of the technical goals for four Phase I grants from the National Institutes of Health (NIH). The Phase I grants were awarded through the NIH Small Business Innovation Research (SBIR) program in 2015 […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-03-08 19:55:442017-12-19 13:02:45GigaGen Announces Successful Completion of Technical Goals on Four NIH Grant Projects
The potential of GigaGen’s single cell sequencing and expression platform to revolutionize immunotherapy drug development and target discovery was highlighted in the recent Genome Web story Expanding Single-Cell Technology, GigaGen Moves Forward in Drug Development Market. According to the article: “Single-cell analysis firm GigaGen has made a sharp turn in its business plans over […]
https://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.png00David Johnsonhttps://gigagen.com/wp-content/uploads/Gigagen_Inline_FullColor_RGB-72-350x95.pngDavid Johnson2016-02-17 19:53:042020-06-02 17:50:12GigaGen Highlighted in Genome Web
GigaGen Announces Issue of US Patent for Polyclonal Antibody Production
GigaGen Inc., the leading innovator in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announces that the United States Patent and Trademark Office has issued U.S. Patent No. 9,422,547, covering protein expression methods for the production of polyclonal antibodies from natural immune repertoires. GigaGen has exclusive rights to the patented technology and is […]
GigaGen Highlighted in Biospace.com Story
GigaGen’s development of the world’s first synthetic immune system was covered recently in the Biospace.com story Bay Area’s GigaGen Develops Synthetic Immune System to Harness Antibodies. According to the article, “The development of therapeutics that harness the body’s immune system has exploded in popularity among biotech companies with many investing heavily in research and […]
GigaGen Announces Successful Completion of Technical Goals on Four NIH Grant Projects
GigaGen Inc., a world leader in massively high-throughput immune repertoire single-cell sequencing and protein expression, today announced that it has achieved all of the technical goals for four Phase I grants from the National Institutes of Health (NIH). The Phase I grants were awarded through the NIH Small Business Innovation Research (SBIR) program in 2015 […]
GigaGen Highlighted in Genome Web
The potential of GigaGen’s single cell sequencing and expression platform to revolutionize immunotherapy drug development and target discovery was highlighted in the recent Genome Web story Expanding Single-Cell Technology, GigaGen Moves Forward in Drug Development Market. According to the article: “Single-cell analysis firm GigaGen has made a sharp turn in its business plans over […]